(Reuters) – Pfizer Inc said on Friday the European Medicines Agency granted the company a positive recommendation for of its treatment for a rare disorder that occurs in patients with cardiomyopathy.

The drug, Vyndaqel, is used to treat patients who suffer from a form of amyloidosis, which is a rare, progressive disease characterized by the abnormal buildup of a protein called amyloid in the body’s organs and tissues.

There are no approved treatments for the condition in the European , the company said, adding that the particular form of the disease is life-, with patients living only two to three and a half years following .

Vyndaqel was first approved in 2011 in the European Union for the treatment of a form of nervous system disorder and is currently approved in 45 countries, including Japan, and countries in Europe.

The EMA’s recommendation will now be reviewed by the European Commission and a final decision is expected in the coming months, Pfizer said.

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Rashmi Aich and Anil D’Silva)

Leave a Reply

Your email address will not be published. Required fields are marked *